186430-23-9|CP-320626|1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-|-范德生物科技公司

CP-320626

NMR下载 COA and HPLC MSDS下载
names：
1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-
CAS号：
186430-23-9
MDL Number：
MF(分子式)： C23H23ClFN3O3 MW(分子量)： 443.9
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	CP-320626
英文别名	CP-320626; CP320626; CP 320626.
CAS号	186430-23-9
Inchi	InChI=1S/C23H23ClFN3O3/c24-16-3-6-19-15(12-16)13-20(26-19)22(30)27-21(11-14-1-4-17(25)5-2-14)23(31)28-9-7-18(29)8-10-28/h1-6,12-13,18,21,26,29H,7-11H2,(H,27,30)/t21-/m0/s1
InchiKey	YDCGVASFVACWKF-NRFANRHFSA-N
分子式 Formula	C23H23ClFN3O3
分子量 Molecular Weight	443.9
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	CP-320626(CAS:186430-23-9):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	CP-320626 is a potent inhibitor, synergistic with glucose, of human liver glycogen phosphorylase a (LGPa). It is a possible target for type 2 diabetes therapy. CP320626 is also a potent inhibitor of human muscle GPa.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Ma D, Wang J, Zhao Y, Lee WN, Xiao J, Go VL, Wang Q, Recker RR, Xiao GG. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas. 2012 Apr;41(3):397-408. doi: 10.1097/MPA.0b013e318236f022. PubMed PMID: 22158071; PubMed Central PMCID: PMC3306546.

[2]Vizán P, Sánchez-Tena S, Alcarraz-Vizán G, Soler M, Messeguer R, Pujol MD, Lee WN, Cascante M. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis. 2009 Jun;30(6):946-52. doi: 10.1093/carcin/bgp083. Epub 2009 Apr 15. PubMed PMID: 19369582.

[3] Gregus Z, Németi B. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Toxicol Sci. 2007 Nov;100(1):44-53. Epub 2007 Aug 9. PubMed PMID: 17693424.

[4] Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. Erratum in: Drug Metab Dispos. 2007 Jul;35(7):1246. PubMed PMID: 17194716.

[5] Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ. Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors. Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E366-72. Epub 2005 Mar 29. PubMed PMID: 15797986.

6: Harwood HJ Jr, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, Treadway JL. Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase. J Lipid Res. 2005 Mar;46(3):547-63. Epub 2004 Dec 16. PubMed PMID: 15604516.7: Lee WN, Guo P, Lim S, Bassilian S, Lee ST, Boren J, Cascante M, Go VL, Boros LG. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br J Cancer. 2004 Dec 13;91(12):2094-100. PubMed PMID: 15599384; PubMed Central PMCID: PMC2409791.8: Oikonomakos NG, Chrysina ED, Kosmopoulou MN, Leonidas DD. Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 A resolution. Biochim Biophys Acta. 2003 Apr 11;1647(1-2):325-32. PubMed PMID: 12686153.9: Dubbelhuis PF, Van Sluijters DA, Blommaart EF, Gustafson LA, Van Woerkom GM, Herling AW, Burger HJ, Meijer AJ. Inhibition of autophagic proteolysis by inhibitors of phosphoinositide 3-kinase can interfere with the regulation of glycogen synthesis in isolated hepatocytes. Biochem J. 2002 Dec 15;368(Pt 3):827-33. PubMed PMID: 12371905; PubMed Central PMCID: PMC1223050.10: Andersen B, Westergaard N. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors. Biochem J. 2002 Oct 15;367(Pt 2):443-50. PubMed PMID: 12099891; PubMed Central PMCID: PMC1222892.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开